• PDF / 170,232 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 77 Downloads / 136 Views

DOWNLOAD

REPORT

---

1 S

Myositis and lack of efficacy in invasive ductal breast carcinoma: case report A 44‑year‑old woman developed myositis during treatment with docetaxel for invasive ductal breast carcinoma. Additionally, she also exhibited no response during treatment with cyclophosphamide and epirubicin for invasive ductal breast carcinoma [routes and dosages not stated]. The woman, who presented with a right breast lump to hospital, was diagnosed with invasive ductal breast carcinoma. Initially, the investigations revealed right breast mass with axillary and internal mammary lymph nodes. She started receiving four cycles of cyclophosphamide and epirubicin. Afterwards, positron emission tomography/computed tomography (PET/CT) revealed right breast mass with additional metastases of pre-sternal subcutaneous nodule, right supraclavicular and mediastinal lymph node along with right axillary nodes suggestive of no response to cyclophosphamide and epirubicin. She was further initiated with four cycles of docetaxel and transtuzumab. After four cycles, PET/CT revealed complete metabolic response to docetaxel and transtuzumab with minimal residual right breast lesion. However, PET/CT scan also revealed diffusely increased fluorodeoxyglucose (FDG) uptake in the skeletal muscles significantly around her shoulder and hip girdles. She also reported of a history of joint and muscle pains with weakness involving bilateral lower and upper limbs approximately three weeks after the initiation of docetaxel, which had progressed gradually after subsequent cycle. Docetaxel induced myositis was suspected. Erythrocyte sedimentation rate (ESR) and creatine phosphokinase (CPK) were 41 mm/h and 395 u/L, respectively [duration of treatment to reaction onset not stated]. Docetaxel was discontinued, and prednisolone was initiated, to which she responded quickly. Afterwards, ESR and CPK normalised within a week. A diagnosis of docetaxel-induced myositis was confirmed due to immediate response to prednisolone and discontinuation of docetaxel. Parida G, et al. Rare case of docetaxel-induced myositis detected on fluorodeoxyglucose positron emission tomography/computed tomography in a patient with carcinoma 803501529 breast. Indian Journal of Nuclear Medicine 35: 248-250, No. 3, Sep 2020. Available from: URL: http://doi.org/10.4103/ijnm.IJNM_25_20

0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 19 Sep 2020 No. 1822